Feds: Morning-after pill appeal officially on hold

by Tom Hays
This undated file photo provided by Barr Pharmaceuticals Inc., shows a package of Plan B One-Step, an emergency contraceptive. The federal government on Monday, June 10, 2013 told a judge it will reverse course and take steps to comply with his order to allow girls of any age to buy emergency contraception without prescriptions. (AP Photo/Barr Pharmaceuticals Inc., File)

A government appeal in the legal fight over allowing girls of any age to buy emergency contraception without prescriptions has officially been put on hold.

said Tuesday in a letter to a New York City appeals court both sides have agreed to stop litigating while they await a ruling from a lower-court judge.

The Department of Justice notified U.S. District Judge Edward Korman on Monday it had decided to reverse course and comply with his order to allow sales of the morning-after pills without age or other restrictions. It said it would withdraw the appeal of the order if the judge agrees with its plan to fast-track approval.

It's unclear when and how the judge will address the issue. A woman answering the phone in his chambers declined to comment.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

US to allow morning-after pill for girls of any age

Jun 11, 2013

The Obama administration said Monday it would comply with a judge's order to allow women and girls of any age to purchase emergency contraception, ending its efforts to restrict the drug's availability.

Judge in NYC rips opposition to Plan B order

May 07, 2013

A federal judge, asked by the U.S. government on Tuesday to freeze his plan giving teenage girls broader access to morning-after birth control, instead seized the chance to accuse health officials of taking steps that would ...

Recommended for you

Boxed warnings are common in novel therapeutics

20 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

21 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

22 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments